Advertisement

Topics

Cellectis starts dosing patients in UCART123’s Phase I trial for BPDCN

19:00 EDT 20 Aug 2017 | Net Resources International

Biopharmaceutical firm Cellectis has started dosing patients in a Phase I clinical trial of its universal chimeric antigen receptor T-cell (UCART) product candidate UCART123 to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Original Article: Cellectis starts dosing patients in UCART123’s Phase I trial for BPDCN

NEXT ARTICLE

More From BioPortfolio on "Cellectis starts dosing patients in UCART123’s Phase I trial for BPDCN"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...